JP2024502463A - 治療指数を改善するためのプラスミン耐性ペプチド - Google Patents

治療指数を改善するためのプラスミン耐性ペプチド Download PDF

Info

Publication number
JP2024502463A
JP2024502463A JP2023541501A JP2023541501A JP2024502463A JP 2024502463 A JP2024502463 A JP 2024502463A JP 2023541501 A JP2023541501 A JP 2023541501A JP 2023541501 A JP2023541501 A JP 2023541501A JP 2024502463 A JP2024502463 A JP 2024502463A
Authority
JP
Japan
Prior art keywords
amino acids
active agent
seq
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502463A5 (https=
Inventor
ジョナサン デイヴィッド ガーマン，
マイケル ティミアンスキー，
ダイアナ メイヤー，
Original Assignee
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2024502463A publication Critical patent/JP2024502463A/ja
Publication of JP2024502463A5 publication Critical patent/JP2024502463A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023541501A 2021-01-08 2022-01-07 治療指数を改善するためのプラスミン耐性ペプチド Pending JP2024502463A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163135498P 2021-01-08 2021-01-08
US63/135,498 2021-01-08
US202163147711P 2021-02-09 2021-02-09
US63/147,711 2021-02-09
US202163221874P 2021-07-14 2021-07-14
US63/221,874 2021-07-14
PCT/US2022/011716 WO2022150655A1 (en) 2021-01-08 2022-01-07 Plasmin-resistant peptides for improved therapeutic index

Publications (2)

Publication Number Publication Date
JP2024502463A true JP2024502463A (ja) 2024-01-19
JP2024502463A5 JP2024502463A5 (https=) 2024-12-27

Family

ID=82357479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541501A Pending JP2024502463A (ja) 2021-01-08 2022-01-07 治療指数を改善するためのプラスミン耐性ペプチド

Country Status (10)

Country Link
US (1) US20240301003A1 (https=)
EP (1) EP4274596A4 (https=)
JP (1) JP2024502463A (https=)
KR (1) KR20230141958A (https=)
AU (1) AU2022206444A1 (https=)
BR (1) BR112023013640A2 (https=)
CA (1) CA3203688A1 (https=)
IL (1) IL304301A (https=)
MX (1) MX2023008086A (https=)
WO (1) WO2022150655A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11080495B2 (en) * 2018-10-25 2021-08-03 Unified Information Devices, LLC Animal motion and temperature monitoring
WO2024149230A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 一种神经保护性psd-95多肽抑制剂及其应用
EP4706670A1 (en) 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514365A (ja) * 2011-05-13 2014-06-19 ケベンハウンス ウニヴェルジテート（ユニバーシティ オブ コペンハーゲン） 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DK2120987T3 (en) 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA3018494C (en) 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2014356912B2 (en) 2013-12-01 2019-08-01 University Of Copenhagen Fatty acid derivatives of dimeric inhibitors of PSD-95
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514365A (ja) * 2011-05-13 2014-06-19 ケベンハウンス ウニヴェルジテート（ユニバーシティ オブ コペンハーゲン） 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤

Also Published As

Publication number Publication date
CA3203688A1 (en) 2022-07-14
KR20230141958A (ko) 2023-10-10
BR112023013640A2 (pt) 2023-12-05
EP4274596A4 (en) 2024-12-25
IL304301A (en) 2023-09-01
US20240301003A1 (en) 2024-09-12
MX2023008086A (es) 2023-08-01
AU2022206444A1 (en) 2023-07-20
WO2022150655A1 (en) 2022-07-14
EP4274596A1 (en) 2023-11-15
AU2022206444A9 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP7143374B2 (ja) 虚血のための組み合わせ療法
JP6220371B2 (ja) 神経疾患の治療のためのモデル系及び治療計画
JP2024502463A (ja) 治療指数を改善するためのプラスミン耐性ペプチド
US10046060B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN104053448B (zh) 一种蛛网膜下腔出血及局部缺血的治疗方法
JP2023511057A (ja) 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
US20230139826A1 (en) Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
US20230285504A1 (en) Inhibition of reperfusion injury with a psd-95 inhibitor
CN116897051A (zh) 用于提高治疗指数的抗纤溶酶肽
HK40096295A (zh) 用於提高治疗指数的抗纤溶酶肽

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421